BHC at a glance
Bausch Health Companies Inc (BHC, SEC CIK 885590) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bausch Health Companies Inc (BHC) reported revenue of $10.3 billion (up 6.7% from FY2024) and net income of $157.0 million. Diluted EPS was $0.42.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Bausch Health Companies Inc (BHC) shares worth $656.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Lenar Aimee J. on August 19, 2026 of 36,827 shares at $7.03 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $10.3B
- +6.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $656.0M · +1 vs prior quarter
- Latest 8-K
- Oct 28, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New governance risk: Thomas Appio became Bausch + Lomb interim CEO October 12, 2026
- Management bandwidth risk: Appio’s overlapping CEO roles may create competing demands
- Conflict-of-interest risk: Appio also became Bausch + Lomb chairman in August 2026
- Reputational risk: dual-company responsibilities may create actual or perceived conflicts
Management Discussion & Analysis
- Revenue $2,941M, up 10% YoY from $2,681M, driven by pricing gains and acquisitions
- Operating margin 33.4% vs 23.1% YoY, with operating income $983M vs $619M
- Best segment: Salix revenue $831M, up 16%; worst growth: International revenue $299M, up 5%
- Nine-month operating cash flow $1,714M vs $905M; ending cash $2,488M vs $1,340M
- Near-term headwinds: Xifaxan negotiated pricing effective 2027, generic entry expected 2028, and ongoing tariff and regulatory risks
AI summary of the BHC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $2.94B, up 10%; Adjusted EBITDA $1.305B, up 32%, signaling strong operating leverage
- GAAP EPS $1.15 versus $0.48; adjusted EPS $1.77 versus $1.16, a 53% increase
Item 2.02: Results of Operations and Financial Condition
- Bausch Health announced third-quarter results for the quarter ended September 30, 2026
- Press release includes financial information as of and for the quarter ended September 30, 2026
Item 2.02: Results of Operations and Financial Condition
- Press release announces Bausch Health’s results for quarter ended June 30, 2026
- Exhibit 99.1 contains operating results and other financial information for the quarter
Item EX-99.1: Item EX-99.1
- Q2 revenue $2.85B, up 13% reported and 11% organic, indicating broad-based operating momentum
- GAAP EPS $0.68 versus $0.40, while adjusted EPS rose 40% to $1.26
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Michael Goettler resigning from Bausch Health’s Board effective June 30, 2026
- Departure tied to his appointment as President and CEO of Knoa Pharma LLC
Item 7.01: Regulation FD Disclosure
- Press release announces Mr. Goettler’s resignation, signaling a senior leadership transition
- Investor focus: successor appointment, timing, and potential strategy or execution impact
AI summaries of BHC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BHC
Don't miss the next BHC filing
- Alerts as it files. A push when BHC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BHC, by share count.
- Ask anything. An AI agent that reads every BHC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Paulson John | A | Sep 30, 2026 | 10,720 | $5.83 |
| WECHSLER AMY B | A | Sep 30, 2026 | 1,179 | $5.83 |
| LEUNG SANDRA | A | Sep 30, 2026 | 5,789 | $5.83 |
| Lenar Aimee J. | Sell | Aug 19, 2026 | 36,827 | $7.03 |
| Lenar Aimee J. | F | Jul 17, 2026 | 5,260 | $4.83 |
| Lenar Aimee J. | F | Jul 15, 2026 | 23,395 | $4.89 |
| LEE STEVEN HYOSIG | F | Jul 14, 2026 | 3,125 | $4.75 |
| Lee Frank D. | Sell | May 19, 2026 | 24,456 | $5.43 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $9.6B | $10.3B |
| Operating Income | - | $1.5B | $1.8B |
| Net Income | -$592.0M | -$46.0M | $157.0M |
| Op. Margin | - | 16.1% | 17.7% |
| Net Margin | - | -0.5% | 1.5% |
| Balance Sheet | |||
| Total Assets | $27.4B | $26.5B | $26.4B |
| Equity | - | -$1.3B | -$554.0M |
| ROE | - | 3.6% | -28.3% |
| Per Share | |||
| EPS | $-1.62 | $-0.13 | $0.42 |
| Cash Flow | |||
| Operating CF | - | $1.6B | $1.4B |
| CapEx | $215.0M | $337.0M | $397.0M |
Source: XBRL data in Bausch Health Companies Inc (BHC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BHC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $656.0M |
| Q2 2026 | 23 | $506.9M |
| Q1 2026 | 23 | $532.0M |
| Q4 2025 | 24 | $738.0M |
| Q3 2025 | 24 | $630.0M |
| Q2 2025 | 23 | $604.0M |
| Q1 2025 | 21 | $580.3M |
| Q4 2024 | 18 | $750.4M |
- Two Sigma Investments+5.27M (+247%)
- Goldman Sachs Group+1.52M (+24%)
- Citadel Advisors LLC+1.06M (+96%)
- D.E. Shaw & Co+818.9K (+30%)
- Renaissance Technologies LLC+730.7K (+55%)
- JPMorgan Chase & Co−491.5K (-56%)
- Dimensional Fund Advisors−207.9K (-6%)
- Marex Group plc−55.2K (-66%)
- Morgan Stanley−42.9K (-3%)
- Vanguard Capital Management LLC−20.9K (-0%)
- U.S. Bancorp+861
Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BHC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 15, 2026 | - | - | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 19, 2026 | - | - | |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | - | |
| 8-K | Apr 29, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
| 4 | Feb 27, 2026 | - | - | - |
| 4 | Feb 27, 2026 | - | - | - |
| 4 | Feb 27, 2026 | - | - | - |
| 10-K | Feb 19, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 18, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BHC SEC filings: frequently asked questions
Which institutions hold BHC stock?
As of September 30, 2026, the largest Bausch Health Companies Inc (BHC) holders among the 13F filers tracked by SignalX were Paulson & Co ($427.1 million), Goldman Sachs Group ($45.2 million), Vanguard Capital Management LLC ($43.4 million), Two Sigma Investments ($43.2 million), D.E. Shaw & Co ($20.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BHC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bausch Health Companies Inc (BHC) reported revenue of $10.3 billion (up 6.7% from FY2024) and net income of $157.0 million. Diluted EPS was $0.42. The figures come from the XBRL data in the 10-K.
What did BHC report in its latest 8-K?
Bausch Health Companies Inc (BHC) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $2.94B, up 10%; Adjusted EBITDA $1.305B, up 32%, signaling strong operating leverage.
What are the latest BHC SEC filings?
Bausch Health Companies Inc (BHC) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on October 2, 2026.
What is BHC's SEC CIK number?
Bausch Health Companies Inc (BHC)'s SEC Central Index Key (CIK) is 885590. EDGAR lists every BHC filing under that number.
Ask anything about BHC
The research agent reads BHC's filings, financials, insider trades and 13F holders, then answers with sources.